FDA will issue a formal Safety Communication on ibogaine cardiac risks before August 10, 2026, and this will create a measurable regulatory divergence in IND approval timelines between natural ibogaine and synthetic analogue (e.g., tabernanthalog, TBG) applications.

The FDA will issue a cardiac safety warning about natural ibogaine, and this will push regulators to treat synthetic versions (engineered in labs to remove cardiac risk) differently—approving or moving faster on the engineered versions while slowing natural ibogaine development. This creates a two-track system where the natural compound and its engineered cousins follow different FDA pathways.

This is a more specific and falsifiable version of the ibogaine FDA prediction. The divergence claim is resolvable by comparing IND approval or clinical hold rates for natural vs. synthetic ibogaine analogues in public FDA records. However, August 10, 2026 is only ~3 months away, making a formal Safety Communication in that window unlikely given FDA's typical communication cadence. Confidence reduced accordingly. The divergence prediction is plausible but hard to verify without IND data.